NCT01430130 (IMPROVE) is a NA clinical trial of embrace device in Hypertrophic, sponsored by Neodyne Biosciences, Inc..

Who is sponsoring NCT01430130?

NCT01430130 is sponsored by Neodyne Biosciences, Inc..

What drugs are being tested in NCT01430130?

Interventions in NCT01430130: embrace device.

What condition does NCT01430130 study?

NCT01430130 studies Hypertrophic.

Is NCT01430130 still recruiting?

NCT01430130 is currently completed. Last updated 21 November 2014.

Are results published for NCT01430130?

Yes — primary outcome results have been posted to ClinicalTrials.gov. See the outcomes section above for details.

Last reviewed 2014-11-21 · How we verify

NCT01430130: IMPROVE

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Investigation of a Novel Mechanomodulating Polymer to Maximize the Outcomes of Scar Revision Procedures

Completed NA Results posted Last updated 21 November 2014

What this trial tests

NA trial testing embrace device in Hypertrophic in 12 participants. Completed in 1 November 2012.

Timeline

1 September 2011

Primary endpoint
1 November 2012

1 November 2012

Quick facts

Lead sponsor	Neodyne Biosciences, Inc.
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	prevention
Enrollment	12
Start date	1 September 2011
Primary completion	1 November 2012
Estimated completion	1 November 2012
Sites	1 location across United States

Drugs / interventions tested

embrace device

Conditions studied

Hypertrophic — all drugs for Hypertrophic →

Sponsor

Neodyne Biosciences, Inc.

Who can join

Adults 18 to 65, any sex, with Hypertrophic. Patients with the condition only — healthy volunteers not accepted.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

Visual Analogue Scale (VAS)
Time frame: 6 months
Visual Analogue Scale Scar Score (VAS Scar Score) was defined and validated by Duncan et al 2006\[1\]. This scale consists of a 10cm line representing scar quality, with 0 representing normal skin and 10 indicating a poor scar. The assessor places a mark along the line to represent the appearance of the scar. This mark is translated into a score by measuring its position on the 10cm line to one de

Sponsor's own description

Neodyne has developed an investigational dressing for post-operative incision care. Neodyne is conducting this research to study whether the investigational dressing, called the Neodyne Dressing, can minimize scar formation in a simple manner.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

The embrace device significantly decreases scarring following scar revision surgery in a randomized controlled trial.
Lim AF, Weintraub J, Kaplan EN, Januszyk M, et al · · 2014 · cited 75× · PMID 24105084 · DOI 10.1097/01.prs.0000436526.64046.d0

Verify or expand the search:

Other Neodyne Biosciences, Inc. trials

Trials by the same sponsor.

NCT06025513 — De-tensioning Patch, in Subjects With Type 1 Diabetes and Lipohypertrophy · NA · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT01430130 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Neodyne Biosciences, Inc.
Last refreshed: 21 November 2014

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT01430130.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing